Mr. John Gleeson:

On the Chairman's first question, on open disclosure, we started the process of cancer audit in 2010 with a view to ensuring quality assurance and continual improvement and through 2014 decided to review it and then commence, in line with the published HSE open disclosure policy of 2013, an evaluation of what that meant in screening terms, mostly in terms of defining serious incidents. It did not make specific reference to screening, which is different. One is dealing with people who do not have symptoms. It is not like people in hospitals; it is a different cohort of the population. Without trying to not do open disclosure, we went about trying to figure out how best to do it in respect of women we were concerned about because, after all, they had been diagnosed with cervical cancer. We were looking at something before that point in time and how to communicate it but we did develop the process. It took a considerable amount of time, for which I apologise, but the intent was always to let the women know. We looked to practices in England and elsewhere to determine how that might best be done. It was always felt that the treating clinician of the woman at that time was the best channel through which to communicate with her. We would not know the context surrounding her current care and treatment at whatever stage she was at in her plan to address the diagnosis. We did develop and implement the open disclosure and communication policy in respect of treating clinicians. Admittedly there were certainly gaps, for which we apologise, in terms of making sure the information actually got to the women but our intention was always that information we had that related to a woman should be made accessible to her.

Could the Chairman repeat the second question?